Why Preventive Biomarker Testing Is Gaining Ground in Europe

Noncommunicable diseases account for nearly 90% of deaths in the WHO European Region.

By 2050, roughly 30% of the continent’s population will be 65 or older.

Those two facts explain why European leaders are putting more money into prevention.

Between 2019 and 2022, the EU’s prevention share of total health spending rose from just under 3% to over 4%. The European Health Data Space became law in March 2025. Updated screening recommendations now target 90% coverage for key cancers.

Preventive biomarker testing is no longer a fringe wellness add-on. It is becoming a practical tool for earlier detection, lower downstream costs, and better workforce planning. 

Consolidated multi-marker platforms such as the Emerald biomarker test represent the kind of integrated approach that employers and clinics are increasingly evaluating as prevention budgets expand.

For employers, insurers, and clinics, the hard question is where testing can reduce avoidable disease without adding false alarms, uneven follow-up, or compliance risk.

Key Takeaways

Europe now has the policy support, clinical use cases, and data rules to expand focused biomarker screening.

Prevention budgets are expanding. EU prevention spending rose after the pandemic, and the EHDS gives programmes a clearer framework for data access and portability.

Start where evidence is strongest. Biennial FIT, primary HPV DNA testing with self-sampling, ApoB in selected adults, and once-in-a-lifetime Lp(a) have the clearest support.

Treat regulation as part of design. GDPR, IVDR, and clear follow-up pathways should shape procurement decisions from day one.

Pilot with discipline. Define the cohort, consent model, escalation steps, and outcome metrics before you send a single kit.

What Preventive Biomarker Testing Actually Is

Preventive biomarker testing helps find elevated risk in people who feel well.

It measures biological signals in people without symptoms and uses them to sort people into lower- and higher-risk groups, flag early disease, or guide prevention. Samples can include blood, urine, stool, or saliva.

It is different from diagnostic testing, which investigates symptoms that already exist. A strong preventive programme also follows evidence-based rules on who to test, when to test, and what action should follow each result.

FIT is a stool test used in colorectal cancer screening. HPV DNA testing looks for the virus that causes most cervical cancers.

ApoB counts the particles that can enter artery walls and may give a clearer picture than standard LDL-C in people with diabetes, obesity, or high triglycerides. Lp(a) is an inherited lipoprotein linked to cardiovascular risk, and European experts now recommend measuring it once in every adult’s life.

A common mistake is treating a larger panel as automatically better. In prevention, a useful marker is one that changes follow-up care, not one that simply creates more data.

Why Now in Europe: Five Structural Tailwinds

Ageing demographics are unavoidable. With the 65-plus share heading toward 30% by mid-century, late-detected chronic disease creates a rising productivity and cost burden. Earlier risk detection is becoming easier to justify for both public systems and employers.

The disease burden favours upstream action. Cardiovascular disease and cancer still drive a large share of mortality. In December 2022, the Council of the EU updated its cancer screening recommendation, targeting 90% coverage for breast, cervical, and colorectal screening while exploring lung, prostate, and gastric programmes.

Digital infrastructure is stronger than it was five years ago. Teleconsultations made up about 16% of all doctor consultations across 16 EU countries in 2022, well above pre-pandemic baselines. That makes remote sampling, results delivery, and follow-up more realistic, especially where access to in-person care is uneven.

Regulatory clarity is improving. IVDR transitional deadlines were extended with clear milestones: manufacturers must apply to a notified body by May 2025 for class D devices, 2026 for class C, and 2027 for class B and sterile class A. The European Health Data Space Regulation (EU) 2025/327, strengthens individual data control and secure secondary use.

Budgets are starting to follow policy. The prevention spending share rose to over 4% in 2022, which gives payers more room to fund organised screening and targeted biomarker programmes.

Where Biomarker Screening Works Today

Colorectal Cancer Screening

For average-risk adults, the EU’s JRC working group recommends biennial FIT up to about age 74. Good implementation still matters, because automated invitations, mailed kits, reminders, and clear colonoscopy pathways determine whether the programme works in practice.

Cervical Cancer Screening

EU-level guidance recommends primary HPV DNA testing, not cytology or co-testing. Mailed HPV self-sampling can substantially increase participation, with meta-analysis suggesting roughly a two-fold improvement.

This is especially useful for people who miss clinic-based screening, but it still requires multilingual instructions and reliable reflex cytology pathways.

Cardiovascular Risk Screening

Traditional lipid panels still matter, but the 2019 ESC/EAS guideline recommends ApoB for risk assessment in people with diabetes, obesity, or high triglycerides.

European experts also advise measuring Lp(a) at least once in every adult’s lifetime to identify inherited cardiovascular risk.

These markers add value when paired with blood pressure, smoking status, and diabetes screening, as shown by practical models such as England’s NHS Health Check for adults aged 40 to 74.

Use Caution With Newer Tests

Prostate screening needs risk-adapted pathways with shared decision-making and MRI triage, not blanket PSA testing.

For newer multi-cancer blood tests, evidence remains immature. Guarded pilots prevent overdiagnosis, weak follow-up, and unnecessary anxiety.

Regulation and Data Governance Essentials

Good governance determines whether a pilot is safe, legal, and scalable.

GDPR Article 9 governs health data. You need explicit consent or another Article 9(2) legal basis, plus data protection impact assessments and vendor processing agreements.

Dual-layer consent, one layer for the programme and another for any secondary data use, helps avoid confusion later.

IVDR determines market access. Confirm CE-mark status, risk class, performance claims, and validated specimen types for every test in your panel.

EHDS improves portability. Plan now for patient access, record transfer, and possible research permissions.

Aligning metadata and coding standards early reduces delays when a pilot expands across borders or business units. For a current view of how European health data governance frameworks are reshaping lab and diagnostic procurement, the shift toward EHDS-ready, IVDR-compliant platforms is already influencing tender requirements across Germany, France, and Italy.

Data governance is only half the job. Positive findings also need timely clinician review, confirmatory testing when needed, and plain-language communication so participants know what a result does, and does not, mean.

Solution Checklist: Shortlist Vendors for Your Pilot

Define your requirements before you compare vendors. That step prevents you from buying capability you do not need, or missing compliance gaps that only appear after launch.

Check CE-mark scope and IVDR class first. Confirm that each biomarker matches a guideline-supported use case, specimen type, and reporting standard.

Review self-sampling options, multi-country logistics, language localisation, external quality assessment, clinician review pathways, dashboard design, SLAs, and unit economics.

When you compare vendors, using one consistent benchmark across biomarker coverage, reporting depth, logistics, governance controls, and follow-up support makes practical gaps easier to spot before procurement.

If you want a consolidated multi-marker panel to reduce test fragmentation in a pilot, the Emerald biomarker test can serve as a neutral reference point when you compare biomarker breadth, reporting quality, and data-governance readiness.

It is one option among several, and any buyer should verify EU regulatory alignment before making a purchase decision.

Frequently Asked Questions

Is Biomarker Testing the Same as Population Screening?

No. Population screening follows strict age, interval, and quality rules set by public health authorities. Many biomarker panels are used for risk assessment in defined cohorts rather than whole populations.

Are At-Home Self-Sampling Kits Reliable?

For FIT and HPV self-sampling, strong evidence supports high participation and acceptable performance under quality assurance. For other markers, verify that the specimen type is validated under IVDR before you scale the programme.

What KPIs Should Go to the Board?

Focus on participation rate, positivity rate versus expected baseline, follow-up completion, risk reclassification, and cost per clinically significant detection.

Report results by site and cohort each quarter. If possible, track equity gaps by language or deprivation quintile so leaders can see who the programme is reaching and who it is missing.